Company filings, made visual.

Find a company. Follow its revenue through costs and profit.

Market

Find a company or ticker

Coverage includes separate ticker and security records; counts are not unique companies.

Precigen, Inc.

PGEN

Filing: SEC 10-Q
Period: Three months ended March 31, 2026
Basis: Editorial filing; Read original SEC 10-Q ↗

Sankey diagram of Precigen, Inc.. A complete text table follows the diagram.

Precigen gene-and-cell therapy platform

Gene and cell therapies target cancer and serious diseases through a focused clinical pipeline.

Swipe to explore

Source & review

Read original SEC 10-Q ↗

SEC accession: 0001356090-26-000017
Filed: Date not recorded
Reviewed: Date not recorded
Status: Individual filing review complete

How to read these figures

Labels and displayed flow values are reported filing values or exact disclosed subtotals.

Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.

Values are in millions of USD unless otherwise noted.

View accessible tables

Financial categories · Three months ended March 31, 2026 · Millions of USD
Category	Stage	Value	Notes
Total reported revenue	1	$23.3M	Reported filing total
Gene-and-cell therapy platform	2	$23.3M	Company-specific editorial view

Financial flows · Millions of USD
From	To	Value
Total reported revenue	Gene-and-cell therapy platform	$23.3M